Peter D. Emanuel
Professor
Also affiliated: Southern Research Institute (1998); Oslo University Hospital (2002); Atrium Health Wake Forest Baptist (1998); National Institutes of Health (1998); U.S. National Science Foundation (2002); Memorial Sloan Kettering Cancer Center (2000); Children's Hospital of Los Angeles (1998); Johns Hopkins University (2002); The University of Texas at San Antonio Health Science Center (2002); University of California, San Francisco (1998); Sanford Burnham Prebys Medical Discovery Institute (1998); University of Washington (2006); University of South Florida (1994); University of Arkansas Medical Center (2008–2018); Norwegian Cancer Society (2002); Cancer Institute (WIA) (2014–2016); Saint Vincent Health System (2020–2021); Catholic Health Initiatives (2020–2021); Moffitt Cancer Center (1994); Cegep de Sept Iles (2002); Children's of Alabama (1998); University of Alabama at Birmingham (1990–2009); University of Chicago (2006); Universitas Sari Mutiara Indonesia (2016); Arcadia (2005–2007); Birmingham VA Medical Center (2002); Greenfield Research (Canada) (2002); Creative Commons (2025); Hospital de Santa Cruz (2015); Duke Medical Center (2002); Cancer Research Center (1998); Winthrop Rockefeller Foundation (2008–2025); Children's Hospital of Pittsburgh (1997); Children's Oncology Group (2005–2007); St. John Hospital & Medical Center (2002); Stanford Medicine (2020); National Cancer Institute (1998); Arkansas Department of Agriculture (2014); UCSF Helen Diller Family Comprehensive Cancer Center (2006); U-M Rogel Cancer Center (2005); Wake Forest University (1998)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Peter D. Emanuel studies pediatric myeloid neoplasms, focusing on their genomic landscape and clonal architecture. His research investigates juvenile myelomonocytic leukemia, examining the sensitivity of its stem cells to natural killer (NK) cell-mediated lysis and identifying targetable antigens. Emanuel also explores potential therapeutic targets for myeloid proliferation neoplasia, including investigations into MLN0128 as a treatment that may prolong survival.
Emanuel is a principal investigator on a federal grant from the NIH/National Institute of General Medical Sciences for the acquisition of a NovaSeq X Plus Advanced Next Generation Sequencer. This instrument supports his work in genomics and related areas.
His scholarship metrics include an h-index of 32, with 108 total publications and 3,565 total citations. He is recognized as a high-impact researcher, indicated by his high citation count. Emanuel collaborates with Y. Lucy Liu at the University of Arkansas for Medical Sciences, with whom he has co-authored two publications.
Metrics
- h-index: 32
- Publications: 108
- Citations: 3,579
Selected Publications
-
Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens (2025)
-
Sustained fetal hematopoiesis causes juvenile death from leukemia: evidence from a dual-age–specific mouse model (2020)
-
PTEN is indispensable for cells to respond to MAPK inhibitors in myeloid leukemia (2018)
-
Unleashing natural killer cells upon immunization with a carbohydrate mimetic peptide vaccine. (2018)
-
Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects (2017)
-
Managing Expectations in the Transition to Proof of Concept Studies (2017)
-
Fludarabine, Melphalan, and Alemtuzumab Conditioning Regimen in High Risk Leukemia: The Arkansas Experience (2017)
-
The Dosage of Pten Is Critical in Determining the Disease Severity - a Mouse Model Differentially Mimicking JMML and CMML (2016)
-
Patterns of Incidence and Survival of Therapy Related Myeloid Neoplasms in United States (2016)
-
JQ1, a Potential Therapeutic Molecule for Myeloid Leukemia with PTEN Deficiency (2016)
-
A rare case of blastic plasmacytoid dendritic cell neoplasm with deletion 7q.31, in the setting of heavy pre-treatment with alkylating chemotherapy (2016)
-
Incidence and survival of chronic myelomonocytic leukemia (CMML) in the United States (US). (2015)
-
Outcomes of primary plasmacytoma (PP) in United States (US). (2015)
-
Overall Outcomes of Bing-Neel Syndrome after Treatment - a Review of 40 Cases (2015)
-
MYC amplification in multiple marker chromosomes and EZH2 microdeletion in a man with acute myeloid leukemia (2015)
Federal Grants 1 $750,000 total
Collaboration Network
Top Collaborators
- Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens
- Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens
- Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens
- Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens
- Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens
- Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens
- Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens
- Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens
- Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens
Similar Researchers
Based on overlapping research topics